Atrial natriuretic peptide as a marker of heart failure in children with left ventricular volume overload

Journal of Paediatrics and Child Health

Volumn 49, Issue 1, 2013, Pages 43-47

  Kotby, Alyaa A ^a   Taman, Khaled H ^b   Sedky, Heba Tallah A ^a   Habeeb, Nevin M M ^a   El Hadidi, Eman S ^a   Yosseif, Hanan S ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b Institute of Postgraduate Childhood Studies   (Egypt)

^c Mubarak Police Hospital   (Egypt)

Author keywords

ANP; heart failure; left ventricular volume overload

Indexed keywords

ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADOLESCENT; AORTA VALVE REGURGITATION; ARTICLE; ATRIOVENTRICULAR SEPTAL DEFECT; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART INJURY; HEART LEFT RIGHT SHUNT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE SEPTUM DEFECT; HUMAN; MALE; MITRAL VALVE REGURGITATION; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC HEART DISEASE; SCHOOL CHILD; SYSTOLIC DYSFUNCTION; TRICUSPID VALVE REGURGITATION;

ADOLESCENT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DUCTUS ARTERIOSUS, PATENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART SEPTAL DEFECTS; HEART VALVE DISEASES; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; RHEUMATIC HEART DISEASE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84872492491     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/jpc.12012     Document Type: Article

References (19)

1. Federico C,. Natriuretic peptide system and cardiovascular disease. Hear Views 2010; 11: 10-15.
2. Bettencourt PM,. Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives. Heart 2005; 91: 1489-1494.
3. Kula S, Tunaoglu FS, Olgunturk R, Gokcora N,. Atrial natriuretic peptide levels in rheumatic mitral regurgitation and response to angiotensin converting enzyme inhibitors. Can. J. Cardiol. 2003; 19: 405-408.
4. Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231: 1145-1147.
5. Danik JS, Bulwer BE,. Mitral regurge. In:, Solomon SD, ed. Essential Echocardiography. Chapter 14. Totowa, NJ: Human Press, 2007; 255-283.
6. Appleton CP, Hatle LK, Popp RL,. Relation of transmitral flow velocity patterns of left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J. Am. Coll. Cardiol. 1988; 12: 426-440.
7. Pettersen MD, Du W, Skeens ME, Humes RA,. Regression equation for calculation of z scores of cardiac structures in a large cohort of healthy infants, children and adolescents; an echocardiographic study. J. Am. Soc. Echocardiogr. 2008; 21: 922-934.
8. Haycock GB, Schwartz GI, Wisotsky DH,. Geometric method for measuring body surface area, a height, weight formula validated in infants, children and adults. J. Pediatr. 1978; 93: 62-66.
9. Kum LC, Yip GW, Lee PW, et al. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. Int. J. Cardiol. 2008; 125: 16-21.
10. Knirsch W, Tlach L, Stambach D, Bauersfeld U,. Angiotensin-converting enzyme inhibitors in pediatric patients with mitral valve regurgitation-case- control study and review of the literature. Congenit. Heart Dis. 2010; 5: 278-284.
11. Nemoto S, Hamawaki M, Freitas G, Carabello BA,. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta adrenergic blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation. J. Am. Coll. Cardiol. 2002; 3: 149-154.
12. Vaz Pérez A, Doehner W, von, Haehling S, et al. The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int. J. Cardiol. 2010; 141: 39-43.
13. Groenning BA, Nilsson JC, Sondergaard L, Kjaer A, Larsson HBW, Hildebrandt P,. Natriuretic peptides are potent markers for left ventricular dimensions and mass in chronic heart failure (Abstract). Circulation 2000; 102: II-782.
14. Hua Q, Wang JR, Shi SY,. Influence of cardiac structure, blood flow velocity and heart function on circulating atrial natriuretic peptide and renin-angiotensin system. Zhonghua Nei Ke Za Zhi 1994; 33: 165-167.
15. Sutton TM, Stewart RA, Gerber IL, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J. Am. Coll. Cardiol. 2003; 41: 2280-2287.
16. Westerlind A, Wahlander H, Lindstedt G, Lundberg PA, Holmgren D,. Clinical signs of heart failure are associated with increased levels of natriuretic peptide type B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr. 2004; 93: 340-345.
17. Clerico A, Iervasi G,. Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: how do they relate to the resistance to atrial natriuretic peptides? J. Card. Fail. 1995; 1: 323-328.
18. Peichota M, Banach M, Jacon A, Rysz J,. Natriuretic peptides in cardiovascular diseases. Cell. Mol. Biol. Lett. 2008; 13: 155-181.
19. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD,. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am. J. Cardiol. 1996; 77: 828-831.